News

Biggest changes for 10 years: earlier ART, treatment as prevention, efavirenz dropped… and new challenges for the NHS… New online guide and A5 booklet.

IAS 2015 – a time of global change for HIV care: over a dozen reports on why this conference news is so exciting…

START results in full, WHO recommends ART for all, HIV cure research, webcasts access, treatment as prevention in HPTN 052, HIV remission in a teenager, dispersible dolutegravir for kids, new ARVs and more…

Activist review of latest research into HIV, HCV and TB: drugs for adults and children, dose optimisation, diagnostics, prevention, cure and vaccines…

Remembering Professor Martin Fisher, breaking news on the START study, reports from BHIVA, CROI and HIV & Women conferences and much more…

On Thursday 2 June, health activists led by ACT UP London held a protest in Soho to demonstrate access to PrEP for people at high risk of HIV infection. The demonstration was loud and active – forming a line from …

This blog is mainly a link page to three recent articles about the START study. A technical report in HIV Treatment Bulletin mainly for health professionals. i-base.info/htb/28261 A non-technical report to explain the implications of the results for HIV positive …

What is the START study? The START study is a large international HIV study. It looks at the risks and benefit of early HIV treatment. “Early” is defined as having a CD4 count above 500. Results are compared to a …

At least 18 months earlier than expected, these results will change treatment guidelines globally…

This talk was for the British HIV Association spring conference. It was a small study lead by advocates at i-Base and was selected by the conference for an oral presentation (Abstract O_4). The study calculated readability scores from nine ongoing …

News, comment and reviews of more than 50 studies in 16 articles from CROI 2015 and 4 from the International Drug Resistance Workshop…

All about PrEP – 6 studies plus ART prevention, 3-drug ART for PMTCT, HIV drug resistance, new drugs: TAF and maturation inhibitors, why TEMPRANO does not support early ART, weekends-off ART for some young people…

Reports from hepatitis and TB meetings, dolutegravir in England, new London guidelines, India rejects patent for Gilead’s sofosbuvir, plus more…

NHS England approves dolutegravir and Triumeq and London guidelines updated for when these drugs can be prescribed…

A definition of ChemSex, proposed by activists from 56 Dean Street and ReShape makes the essential distinction between ChemSex and recreational drugs for sex. ChemSex is NOT the same as recreational drug use. It is a specific form of recreational drug …

PrEP works. NHS access needed now. The activist group, ACT-UP London organised a community demonstration this morning to support the advisory group working on access to PrEP. Great to see support from ACT-UP, ReShape, Positively UK, i-Base,  THT and others. With 6000 people diagnosed with HIV in 2013 …

Stock-outs in the UK, conference reports from Glasgow, BHIVA and South Africa, plus the PROUD and IPERGAY studies and new UK data show urgency of PrEP access…

A couple of weeks ago I gave a talk about PrEP from a community perspective to the HIV conference in Glasgow. The talk lasts for 20 minutes with questions afterwards and is now available as a webcast on the conference website. …

Talk about PrEP (Pre-Exposure Prophylaxis) from the HIV Conference in Glasgow. The talk looks at the history of PrEP and a few myths. Although optimal use will be in situations where HIV risk is high, PrEP – just like TasP (Treatment …

This is a pre-press article for the November/December edition of HTB. Simon Collins, HIV i-Base Serious vision loss linked to recreational use of poppers has been reported as a case study in this weeks issue of the Lancet. The vision …